Market Overview

Mylan Pharma Wins Final FDA Approval for ANDA for Phenytoin Chewable Tablets, 50 mg

Related MYL
Teva Beats Q3 Earnings Expectations, Updates Outlook
Earnings Scheduled For October 30, 2014
Will Congress Scuttle the AbbVie-Shire Merger? (Fox Business)
Related PFE
When There's A Pullback On A Bull, Look At These Leading ETFs
U.S. Markets Recover From Early-Day Losses As Japan's Economy Contracts
Divided Government Won't Halt Street's Run (Fox Business)

Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Phenytoin Chewable Tablets USP, 50 mg. This product is the generic version of Pfizer's Dilantin® Chewable Tablets, which are indicated for the control of generalized tonic-clonic (grand mal) and complex partial (psychomotor, temporal lobe) seizures and prevention and treatment of seizures occurring during or following neurosurgery. Phenytoin serum level determinations may be necessary for optimal dosage adjustments.

Posted-In: News FDA


Related Articles (MYL + PFE)

Around the Web, We're Loving...

Get Benzinga's Newsletters